HomeAI · summaries
Storia in 3 fonti
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Capvaxive approved for children at high risk for pneumococcal disease
The FDA has expanded the approval of Merck’s 21-valent pneumococcal vaccine to include children at increased risk for pneumococcal disease, the drug maker announced…
- ·
morningstar.com
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2…
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for…
